Skip to main content

Table 1 Patient characteristics

From: Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer

  LDR-BT (n = 445) IMRT (n = 165) p value
Age (year)
 Median (range) 71 (48–83) 74 (51–84) <0.001 b
PSA at diagnosis (ng/mL)
 Median (range) 7.1 (3.1–43.6) 14.1 (2.8–364) <0.001 c
Biopsy Gleason score
 6 or less 245 37  
 7 173 76  
 8–10 27 52 <0.001 a
Clinical T stage
 T1b/1c 0/238 2/44  
 T2a/2b/2c 143/35/21 30/10/5  
 T3a/3b 8/0 42/32 <0.001 a
Neoadjuvant/Adjuvant ADT
 None 267 34  
 neo-Ad (+) 141 24  
 Ad (+) 10 14  
 neo-Ad (+), Ad (+) 27 93 <0.001 a
Risk stratification
 Low 184 17  
 Intermediate 201 36  
 High 60 112 <0.001 a
BED (Gy2)
 Median (range) 199.2 (120.3–253.2) 148 (148–152) <0.001 b
Follow-up period
 Median (range) 75 (3–143) 78 (18–125) 0.118 b
Prescribed dose (Gy)
 74   107  
 76   58  
 110 141   
 145 97   
 160 207   
EBRT
 No 300   
 Yes 145   
  1. BED biological effective dose, ADT androgen deprivation therapy, Neoad neoadjuvant, Ad adjuvant, EBRT external beam radiation therapy
  2. aChi-square test
  3. bt-test
  4. cMann-Whitney U test